« Return to News | CROs/Service Providers

Calvert Laboratories inks deal with Particle Sciences on early-stage development

Monday, March 18, 2013 11:53 AM

Calvert Laboratories and Particle Sciences, two CROs in the fields of preclinical toxicology and drug product formulation, have joined forces to offer a streamlined solution to expedite preclinical drug development activities. 

This partnership aims to alleviate delay issues by aligning formulation and preclinical experts, enabling them to identify the problem and realize the solution more quickly.  Through this collaboration, Particle Sciences develops a formulation specifically aimed at achieving the desired exposure levels to allow Calvert Labs to seamlessly carry out the testing component of the project.

“Formulation is often one of the most significant challenges our clients’ face.  The sooner we can resolve any issues, the more quickly we can help them advance their program forward,” said Charles B. Spainhour, V.M.D, Ph.D., president and chief scientific officer, Calvert Labs.

Mark Mitchnick, M.D., CEO of Particle Sciences, added, “No single group has the in-depth expertise in both formulation and toxicology needed to tackle this.  Through this combined effort, under a single scope of work, our clients are getting a very valuable service unavailable anywhere else.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.